Pfizer conference takeaways were positive overall, but Goldman Sachs maintains a Neutral rating and $26 target price

Overview

This report summarizes key discussion points from Pfizer Chairman and CEO Albert Bourla at Goldman Sachs' 47th Annual Global Healthcare Conference. The overall tone was constructive: management emphasized that the non-COVID business drove recent results above expectations, cost reductions—especially in manufacturing—supported margin expansion, and AI together with China's competitive landscape is pushing the industry toward lower costs and higher efficiency. At the company level, the discussion focused on business development capabilities, potential upward pressure on 2026 guidance, the obesity portfolio, and key pipeline assets such as the PD-1xVEGF bispecific antibody and Sig Vedotin.

Core views

Goldman Sachs' core view is as follows: first, Pfizer's fundamentals are more stable than before, with the non-COVID business supporting Q1 2026 revenue and EPS above expectations, though the company remains disciplined in not rushing to raise full-year guidance after the first quarter; second, COVID revenue is falling from $11 billion in 2024 and $6.5 billion in 2025 to about $5 billion in 2026, but cost reductions have offset part of the pressure; third, the obesity business could become an important medium- to long-term growth driver, with the convenience, cost, and manufacturing capacity of berobenatide's monthly formulation serving as differentiators; fourth, the oncology pipeline has important catalysts, especially the mid-year readout for Sig Vedotin in 2L NSCLC and the subsequent 1L Keytruda combination readout; fifth, despite the constructive tone of the meeting, Goldman Sachs maintains a Neutral rating, viewing risks and potential returns as relatively balanced.

Analysis framework

The report adopts a conference-notes format, analyzing the operating environment, business development, regulatory environment, AI and China competition, obesity, and the oncology pipeline based on management commentary, while also summarizing Goldman Sachs' views on valuation, target price, upside risks, and downside risks. On valuation, Goldman Sachs applies a 9.0x P/E multiple to Q5-Q8 adjusted EPS to derive a 12-month target price of $26.

Methodology notes

• Conference notesManagement interview and conference takeaways

  Extract operating trends, strategic priorities, and clinical catalysts from the CEO's remarks.

  This report is based primarily on management discussion at Goldman Sachs' Global Healthcare Conference, focusing on business trends, the external regulatory environment, M&A capability, AI-driven cost reduction and efficiency improvement, the obesity portfolio, and the oncology pipeline.

• Valuation methods12-month target price valuation

  Apply a 9.0x multiple to Goldman Sachs' Q5-Q8 adjusted EPS.

  On this basis, Goldman Sachs derives a 12-month target price of $26 for PFE and maintains a Neutral rating.

• Factor and M&A frameworkGS Factor Profile and M&A Rank

  Provide investment context through growth, financial returns, valuation multiples, composite factors, and potential M&A probability.

  The appendix states that Goldman Sachs compares individual stocks with the market and industry peers using growth, financial returns, valuation multiples, and composite metrics, and uses M&A Rank to assess the probability that a company becomes an acquisition target.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• PFE.N / PFIZER INC

  Primary subject covered by the report; equity of a large U.S. diversified pharmaceutical company.

  Strengths

  The non-COVID business drove results above expectations; manufacturing cost reductions are improving margins; the obesity portfolio has dosing convenience and cost advantages; the oncology pipeline includes important assets such as Sig Vedotin and the PD-1xVEGF bispecific; the company still has about $7 billion of BD capacity.

  Weaknesses

  The COVID business continues to decline; long-term growth depends heavily on pipeline execution; the vaccine business faces regulatory and commercial uncertainty; the target price is close to the disclosed price, limiting near-term valuation upside.

  Comparison

  The rating is Neutral relative to peers in Goldman Sachs' coverage universe, including AbbVie, BioNTech, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, and Merck.

  Risks

  Late-stage clinical failures, further deterioration in the vaccine business, tariff impacts, Paxlovid sales affected by fluctuations in infection levels, and intensifying global pharmaceutical competition driven by China and AI.

Key data

• RatingNeutralGoldman Sachs maintains a Neutral rating on Pfizer.
• 12-month target price$26Based on applying a 9.0x multiple to Q5-Q8 adjusted EPS.
• Disclosed price$26.04Company price information disclosed in the report.
• 2026 COVID business revenue约$5 billionContinuing to decline from $11 billion in 2024 and $6.5 billion in 2025.
• Long-term revenue targetHigh-single-digit revenue CAGR starting in 2029Management said this is supported by existing products, new launches, LOE products, and the risk-adjusted pipeline.
• Recent M&A investment约$70 billionThe three deals—Seagen, Biohaven, and Metsera—account for about 80% of deployed capital.
• Current BD capacity约$7 billionThe strategic focus is on pipeline-bolstering deals, though larger transactions could also be considered if opportunities are attractive.
• Growth of acquired assetsSeagen portfolio grew 20% this quarter, Biohaven migraine products grew 42%Management cited this to demonstrate recent BD productivity.
• Phase 3 obesity programberobenatide advancing through 10 Phase 3 trialsThe weekly formulation is expected to launch in 2028, followed relatively quickly by the monthly formulation.
• Obesity positioningThe monthly formulation targets 15%-20% weight loss demand, while the amylin/GLP-1 combination targets higher-BMI patients24-28 week data for amylin monotherapy and the combination are expected later this year.
• Oncology catalystsSig Vedotin 2L NSCLC mid-year readout, 1L Keytruda combination readout about one year laterGoldman Sachs believes the bar is higher and the probability of success lower for the 2L monotherapy study, while the 1L combination is relatively more de-risked.
• PD-1xVEGF bispecific4404 program has entered 8 Phase 3 studiesManagement believes its data has best-in-class potential and could offer combination advantages with Seagen ADCs.

Impact & implications

In terms of investment implications, the report signals that Pfizer's earnings resilience and medium- to long-term growth narrative are improving: AI and manufacturing cost reductions support margins, while the obesity and oncology pipelines provide new growth optionality, and the assessment of the regulatory environment is more positive than before. However, Goldman Sachs' target price is close to the disclosed price, suggesting that near-term risk/reward remains fairly balanced; further stock re-rating will require validation from key clinical data, obesity commercialization progress, additional cost savings, or stabilization in the vaccine business.

Risks

• Setbacks in late-stage pipeline assets could reduce long-term earnings expectations and lead to further compression in valuation multiples.
• The vaccine business accounts for a relatively high share of revenue; if regulatory or commercial prospects are weaker than expected, it could weigh on estimates and market sentiment.
• Tariffs could have a relatively larger impact on Pfizer's profits because the company's gross margin is below the Goldman Sachs coverage average.
• The bar is high for Sig Vedotin's 2L NSCLC monotherapy trial; if data disappoints, it would weaken confidence in the near-term oncology pipeline.
• The COVID business continues to shrink, and Paxlovid treatment sales remain affected by uncertainty in infection levels.
• Global competition driven by Chinese pharma companies and AI may force the industry to compete at lower cost and faster speed, compressing the advantages of traditional large pharmaceutical companies.

What to watch

• Mid-year clinical readout for Sig Vedotin 2L NSCLC monotherapy.
• Readout in about one year for the first-line combination trial of Sig Vedotin and Keytruda.
• 24-28 week data for amylin monotherapy and the amylin/GLP-1 combination.
• Progress of berobenatide's 10 Phase 3 trials, as well as the launch timeline for the weekly formulation in 2028 and the subsequent monthly formulation.
• The actual contribution to revenue growth and cost efficiency after broader AI deployment in 2H 2026.
• Changes in FDA, CDC, U.S. drug pricing, and tariff policies.
• Whether the BD strategy expands from smaller bolt-on deals to larger-scale transactions.
• Whether the vaccine business shows signs of stabilization.